Who makes 13-valent pneumococcal conjugate vaccine?

13-valent pneumococcal conjugate vaccine is developed by Pfizer Inc..

What development phase is 13-valent pneumococcal conjugate vaccine in?

13-valent pneumococcal conjugate vaccine is FDA-approved (marketed).

What is the generic name of 13-valent pneumococcal conjugate vaccine?

13-valent-pneumococcal-conjugate-vaccine is the generic (nonproprietary) name of 13-valent pneumococcal conjugate vaccine.

Last reviewed 2026-05-15 · How we verify

13-valent pneumococcal conjugate vaccine (13-valent-pneumococcal-conjugate-vaccine)

Pfizer Inc. · FDA-approved approved Vaccine Quality 5/100

The 13-valent pneumococcal conjugate vaccine, marketed by Pfizer Inc., holds a significant position in the pneumococcal vaccine market. A key strength of this vaccine is its broad coverage against 13 serotypes of Streptococcus pneumoniae, which has contributed to its widespread adoption and strong market presence. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic versions.

At a glance

Generic name	13-valent-pneumococcal-conjugate-vaccine
Sponsor	Pfizer Inc.
Modality	Vaccine
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

13-valent pneumococcal conjugate vaccine CI brief — competitive landscape report
13-valent pneumococcal conjugate vaccine updates RSS · CI watch RSS
Pfizer Inc. portfolio CI